COVID-19 Drug Discovery Using Intensive Approaches

Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.

[1]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[2]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[3]  J. Qi,et al.  Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 , 2020 .

[4]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[5]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[6]  M. Martínez.  Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.

[7]  Jianjun Gao,et al.  Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.

[8]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[9]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[10]  Oon Tek Ng,et al.  Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. , 2020, JAMA.

[11]  M. He,et al.  [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. , 2020, Zhonghua xin xue guan bing za zhi.

[12]  B. Pan,et al.  Understanding of COVID‐19 based on current evidence , 2020, Journal of medical virology.

[13]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[14]  T. Daikoku,et al.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections , 2020, Pharmacology & Therapeutics.

[15]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[16]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[17]  S. Perlman,et al.  Distinct Roles for Sialoside and Protein Receptors in Coronavirus Infection , 2020, mBio.

[18]  W. Zuo,et al.  Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.

[19]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[20]  H. Ishii,et al.  Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells. , 2019, Cancer research.

[21]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[22]  H. Eguchi,et al.  Poly(ethylene glycol)–poly(lysine) block copolymer–ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells , 2018, Oncogene.

[23]  B. Bosch,et al.  Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility , 2018, Proceedings of the National Academy of Sciences.

[24]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[25]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[26]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[27]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[28]  Yu Chen,et al.  Molecular mechanisms of coronavirus RNA capping and methylation , 2016, Virologica Sinica.

[29]  M. Fox,et al.  Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors , 2015, Amino Acids.

[30]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[31]  Giulio Superti-Furga,et al.  Structural basis for viral 5′-PPP-RNA recognition by human IFIT proteins , 2013, Nature.

[32]  Chengyu Jiang,et al.  Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.

[33]  Burkhard Ludewig,et al.  Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5 , 2011, Nature Immunology.

[34]  F. Giles,et al.  Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis* , 2010, The Journal of Biological Chemistry.

[35]  Hongping Dong,et al.  2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members , 2010, Nature.

[36]  K. Mimori,et al.  CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.

[37]  Nicole C. Robb,et al.  RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus Infection , 2010, Cell.

[38]  V. Cowling,et al.  Regulation of mRNA cap methylation , 2009, The Biochemical journal.

[39]  P. Bevilacqua,et al.  A brilliant disguise for self RNA: 5’-end and internal modifications of primary transcripts suppress elements of innate immunity , 2008, RNA biology.

[40]  S. Polyak,et al.  Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. , 2008, Current medicinal chemistry.

[41]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[42]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[43]  Yi Guo,et al.  West Nile Virus 5′-Cap Structure Is Formed by Sequential Guanine N-7 and Ribose 2′-O Methylations by Nonstructural Protein 5 , 2006, Journal of Virology.

[44]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[45]  A. Cassone,et al.  Effects of chloroquine on viral infections: an old drug against today's diseases , 2003, The Lancet Infectious Diseases.

[46]  A. Shatkin,et al.  Viral and cellular mRNA capping: Past and prospects , 2000, Advances in Virus Research.

[47]  S. Shuman,et al.  Accelerated mRNA decay in conditional mutants of yeast mRNA capping enzyme. , 1998, Nucleic acids research.

[48]  B. Pasquier.  Autophagy inhibitors , 2015, Cellular and Molecular Life Sciences.

[49]  J. Darnell,et al.  Transcription units for mRNA production in eukaryotic cells and their DNA viruses. , 1979, Progress in nucleic acid research and molecular biology.